| Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications DK Hiwase, V Saunders, D Hewett, A Frede, S Zrim, P Dang, L Eadie, ... Clinical Cancer Research 14 (12), 3881-3888, 2008 | 229 | 2008 |
| Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib LN Eadie, TP Hughes, DL White Clinical Pharmacology & Therapeutics 95 (3), 294-306, 2014 | 100 | 2014 |
| The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment LN Eadie, P Dang, VA Saunders, DT Yeung, MP Osborn, AP Grigg, ... Leukemia 31 (1), 75-82, 2017 | 68 | 2017 |
| The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro LN Eadie, VA Saunders, S Branford, DL White, TP Hughes Oncotarget 9 (17), 13423, 2018 | 49 | 2018 |
| ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines LN Eadie, TP Hughes, DL White PloS one 11 (8), e0161470, 2016 | 45 | 2016 |
| KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease MO Forgione, BJ McClure, LN Eadie, DT Yeung, DL White Cancer letters 469, 410-418, 2020 | 39 | 2020 |
| Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2 LN Eadie, VA Saunders, TP Hughes, DL White Leukemia & lymphoma 54 (3), 569-578, 2013 | 32 | 2013 |
| CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on … DL White, VA Saunders, P Dang, A Frede, L Eadie, S Soverini, ... Blood 112 (11), 3187, 2008 | 29 | 2008 |
| ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear … LN Eadie, P Dang, JM Goyne, TP Hughes, DL White PLoS One 13 (1), e0192180, 2018 | 28 | 2018 |
| Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells L Eadie, TP Hughes, DL White Leukemia 24 (4), 855-857, 2010 | 15 | 2010 |
| HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort EC Page, SL Heatley, LN Eadie, BJ McClure, CE de Bock, S Omari, ... Oncogene 41 (6), 797-808, 2022 | 13 | 2022 |
| RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL) J Rehn, C Mayoh, SL Heatley, BJ McClure, LN Eadie, C Schutz, ... PLoS Genetics 18 (10), e1010300, 2022 | 12 | 2022 |
| Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy LN Eadie, TP Hughes, DL White Leukemia 32 (10), 2288-2291, 2018 | 12 | 2018 |
| MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies MO Forgione, BJ McClure, DT Yeung, LN Eadie, DL White Genes, Chromosomes and Cancer 59 (12), 709-721, 2020 | 11 | 2020 |
| Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells DL White, LN Eadie, VA Saunders, DK Hiwase, TP Hughes Leukemia 27 (5), 1201-1204, 2013 | 11 | 2013 |
| Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia PT Shirazi, LN Eadie, EC Page, SL Heatley, JB Bruning, DL White Cancer Letters 512, 28-37, 2021 | 10 | 2021 |
| The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL P Tavakoli Shirazi, LN Eadie, SL Heatley, TP Hughes, DT Yeung, ... British Journal of Cancer 122 (4), 455-464, 2020 | 10 | 2020 |
| In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis. DK Hiwase, DL White, VA Saunders, P Dang, A Venables, L Eadie, S Zrim, ... Blood, The Journal of the American Society of Hematology 110 (11), 1937-1937, 2007 | 8 | 2007 |
| Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia PT Shirazi, LN Eadie, SL Heatley, EC Page, M François, TP Hughes, ... Cancer Gene Therapy 29 (8), 1140-1152, 2022 | 4 | 2022 |
| The allosteric inhibitor ABL001 is susceptible to resistance in vitro mediated by overexpression of the drug efflux transporters ABCB1 and ABCG2 LN Eadie, VA Saunders, TM Leclercq, S Branford, DL White, TP Hughes Blood 126 (23), 4841, 2015 | 4 | 2015 |
